Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
4 trials since 2013, 2 ongoing, by the sponsor of the products; see every authorized trial
A phase 2, randomized study of duvelisib administered in combination with rituximab vs r-chop in subjects with…Jun 10, 2016 · Pending · IPI-145 (duvelisib)/ Cyclophosphamide/ Doxorubicin/ Vincristine/ Prednisone/ Rituximab
A phase 1b study of IPI-145 administered in combination with obinutuzumab in patients with CLL/sll previously treated…Dec 22, 2015 · Ongoing · IPI-145/ Obinutuzumab
A phase 3, randomized, double-blind study of duvelisib administered in combination with rituximab and bendamustine vs…Dec 18, 2015 · Pending · Duvelisib (IPI-145)/ Bendamustine/ Rituximab
A randomized, double-blind, placebo-controlled phase 3 study of IPI-145 in combination with rituximab vs rituximab in…Jul 31, 2014 · Ongoing · IPI-145/ Rituximab
Orphan designations (FDA)
2 designations since 1983, 0 approved for the designated use, matched by the sponsor's name; see all orphan designations
RetaspimycinTreatment for gastrointestinal stromal tumor · Aug 31, 2007
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.